2.68
2.90%
-0.08
After Hours:
2.73
0.05
+1.87%
Fate Therapeutics Inc stock is traded at $2.68, with a volume of 1.28M.
It is down -2.90% in the last 24 hours and down -16.77% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$2.76
Open:
$2.81
24h Volume:
1.28M
Relative Volume:
1.05
Market Cap:
$305.19M
Revenue:
$12.32M
Net Income/Loss:
$-175.72M
P/E Ratio:
-1.235
EPS:
-2.17
Net Cash Flow:
$-141.45M
1W Performance:
-1.47%
1M Performance:
-16.77%
6M Performance:
-33.99%
1Y Performance:
+12.13%
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
Jan-06-23 | Downgrade | Stifel | Buy → Hold |
Jan-06-23 | Downgrade | Truist | Buy → Hold |
Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
Dec-15-22 | Initiated | Goldman | Sell |
Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
Oct-10-22 | Initiated | Canaccord Genuity | Buy |
Aug-18-22 | Resumed | Wells Fargo | Overweight |
Jul-28-22 | Initiated | Needham | Hold |
Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jun-03-22 | Initiated | Robert W. Baird | Neutral |
Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
Dec-07-21 | Initiated | Cowen | Outperform |
Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
Apr-26-21 | Resumed | Jefferies | Buy |
Feb-26-21 | Initiated | BofA Securities | Buy |
Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
May-13-20 | Initiated | H.C. Wainwright | Buy |
Mar-04-20 | Initiated | Barclays | Overweight |
Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Dec-30-19 | Reiterated | Mizuho | Buy |
Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
Nov-12-19 | Initiated | SunTrust | Buy |
Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
Oct-01-19 | Initiated | Stifel | Buy |
Aug-09-19 | Initiated | BTIG Research | Buy |
Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
Jul-12-19 | Initiated | Oppenheimer | Outperform |
Jun-13-19 | Initiated | Mizuho | Buy |
Jun-07-19 | Initiated | ROTH Capital | Neutral |
May-31-19 | Initiated | Guggenheim | Buy |
May-24-19 | Resumed | Citigroup | Buy |
Mar-28-19 | Initiated | SVB Leerink | Outperform |
Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
Nov-05-18 | Initiated | Jefferies | Buy |
Aug-01-18 | Initiated | Citigroup | Buy |
Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Drops To US$2.81, Yet Insiders May Have Sold Too Early - Simply Wall St
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionFATE - AsiaOne
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 5.7% in September - MarketBeat
Fate Therapeutics Inc (FATE) looking to reclaim success with recent performance - SETE News
Was Fate Therapeutics Inc (FATE)’s session last reading good? - US Post News
Market Recap Check: Fate Therapeutics Inc (FATE)’s Positive Finish at 3.09, Up/Down 5.10 - The Dwinnex
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Hold" from Analysts - MarketBeat
Fate Therapeutics Inc [FATE] stock was sold by Xu Yuan at the price of US$2678.0 - Knox Daily
Dimensional Fund Advisors LP Has $6.99 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Holdings of Fate Therapeutics Inc (FATE) are aligned with the stars - SETE News
Fate Therapeutics Inc (FATE) Stock: Heads Or Tails? - Stocks Register
The Fate Therapeutics Inc (FATE) Stock Is Headed for a Correction - US Post News
Market Insight: Fate Therapeutics Inc (FATE)’s Notable Gain, Closing at 3.22 - The Dwinnex
Renaissance Technologies LLC Takes Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Fate Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Can you still get a good price for Fate Therapeutics Inc (FATE) Shares at this point? - US Post News
Fate Therapeutics' SWOT analysis: cell therapy stock poised for pivotal year - Investing.com
Investor’s Toolkit: Key Ratios for Assessing Fate Therapeutics Inc (FATE)’s Performance - The Dwinnex
Perceptive Advisors LLC Purchases New Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
You might want to take a look at Fate Therapeutics Inc (FATE) now - SETE News
Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Holdings Lifted by Deerfield Management Company L.P. Series C - MarketBeat
FATE’s Debt-to-Equity Ratio at 0.25: What It Means for Fate Therapeutics Inc’s Future - The InvestChronicle
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bumble Inc. - GlobeNewswire
Fate Trigger The Novita Cinematic Teaser - GameSpot
FTR: Trailer orders remain below expectations - Fleet Equipment Magazine
Should investors be concerned about Fate Therapeutics Inc (FATE)? - US Post News
FendX Provides Corporate Update - Newsfile
Closing Figures: Fate Therapeutics Inc (FATE)’s Negative Finish at 3.87, Down -3.25 - The Dwinnex
Integral Health Asset Management LLC Acquires 650,000 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Acquired by Bank of New York Mellon Corp - Defense World
FTR reports August 2024 trailer orders were below projections - Trucks, Parts, Service
Kaskela Law LLC Announces Shareholder Investigation of Fate - GlobeNewswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $6.90 Consensus Price Target from Brokerages - MarketBeat
Top investors say Fate Therapeutics Inc (FATE) ticks everything they need - SETE News
E Fund Management Co. Ltd. Increases Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Technical analysis of Fate Therapeutics Inc (FATE) stock chart patterns - US Post News
Bruce & Co. Inc. Has $984,000 Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference - GlobeNewswire
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? - Yahoo Finance
Acadian Asset Management LLC Increases Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Stake Lifted by Acadian Asset Management LLC - Defense World
Are Smart Investors Making the Right Decision? Fate Therapeutics Inc (FATE) - SETE News
Examining Fate Therapeutics Inc (FATE) more closely is necessary - US Post News
Financial Analysis: Fate Therapeutics Inc (FATE)’s Ratios Unveil Key Insights - The Dwinnex
There is no way Fate Therapeutics Inc (FATE) can keep these numbers up - SETE News
FATE underperforms with a -5.99 decrease in share price - US Post News
Deeper Dive: Understanding Fate Therapeutics Inc (FATE) Through its Various Ratios - The Dwinnex
Bone Degeneration Therapeutics Market Outlook, Growth By Top - openPR
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):